Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis
Background and Aim Studies had shown that tenofovir (TDF) and entecavir (ETV) are widely used as the first‐line therapy to inhibit hepatitis B virus replication, which can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it was unclear which nucleos(t)ide...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2020-09, Vol.35 (9), p.1467-1476 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1476 |
|---|---|
| container_issue | 9 |
| container_start_page | 1467 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 35 |
| creator | Gu, Lihu Yao, Qigu Shen, Zefeng He, Ying Ng, Derry Minyao Yang, Tong Chen, Bangsheng Chen, Ping Mao, Feiyan Yu, Qili |
| description | Background and Aim
Studies had shown that tenofovir (TDF) and entecavir (ETV) are widely used as the first‐line therapy to inhibit hepatitis B virus replication, which can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it was unclear which nucleos(t)ide analogue was most effective. Therefore, we performed a meta‐analysis and a systematic review to compare the incidence of HCC in CHB patients who are either on TDF or ETV.
Methods
For this study, the following databases were searched for clinical trials published from its inception until November 2019: PubMed, Web of Science, MEDLINE, Embase, and Cochrane Library.
Results
A total of 11 eligible studies were selected, including 70 864 patients. The meta‐analysis showed that TDF was superior to ETV with regard to the incidence of HCC, the incidence of death or transplantation, and virologic response. There were no significant differences in terms of biochemical response and loss of seroconversion response among the entire cohort.
Conclusions
The conclusion was that CHB patients treated with TDF had a reduced incidence of HCC compared with patients treated with ETV. |
| doi_str_mv | 10.1111/jgh.15036 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2377997552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2443725583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4196-bc9690cc559bdb08b745f1dcf076df803c366abf13990dc6ce5250775db205683</originalsourceid><addsrcrecordid>eNp10U1u1DAYBmALUdFpYcEFkCU2dJHWjv9idmVUWqpKbGAdOc6XjkeJPdjJVLPjCNyhN-MkOKSwQMIbW58ev7L1IvSaknOa18X2fnNOBWHyGVpRzklBFZfP0YpUVBSaUX2MTlLaEkI4UeIFOmYlrUjJ9Qo9rsOwM9Gl4HHo8Ag-dGHvIt5DTFPC4EewZh5kEKGdrPP32HnrWvAW5jsb2JkxWOj7qTcRWxOzCYPJCttNDN7ZxbjRJfwBz6ccm97jS5wOaYQhD2wO3zt4wMa3eIDR_Pz-w3jTH5JLL9FRZ_oEr572U_T149WX9U1x9_n60_ryrrCcalk0VktNrBVCN21DqkZx0dHWdkTJtqsIs0xK03SUaU1aKy2IUhClRNuURMiKnaJ3S-4uhm8TpLEeXJr_ZTyEKdUlU0prJUSZ6dt_6DZMMb83K86ZKoWoWFZni7IxpBShq3fRDSYeakrqubk6N1f_bi7bN0-JUzNA-1f-qSqDiwU8uB4O_0-qb69vlshfA-2mYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2443725583</pqid></control><display><type>article</type><title>Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis</title><source>Access via Wiley Online Library</source><creator>Gu, Lihu ; Yao, Qigu ; Shen, Zefeng ; He, Ying ; Ng, Derry Minyao ; Yang, Tong ; Chen, Bangsheng ; Chen, Ping ; Mao, Feiyan ; Yu, Qili</creator><creatorcontrib>Gu, Lihu ; Yao, Qigu ; Shen, Zefeng ; He, Ying ; Ng, Derry Minyao ; Yang, Tong ; Chen, Bangsheng ; Chen, Ping ; Mao, Feiyan ; Yu, Qili</creatorcontrib><description>Background and Aim
Studies had shown that tenofovir (TDF) and entecavir (ETV) are widely used as the first‐line therapy to inhibit hepatitis B virus replication, which can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it was unclear which nucleos(t)ide analogue was most effective. Therefore, we performed a meta‐analysis and a systematic review to compare the incidence of HCC in CHB patients who are either on TDF or ETV.
Methods
For this study, the following databases were searched for clinical trials published from its inception until November 2019: PubMed, Web of Science, MEDLINE, Embase, and Cochrane Library.
Results
A total of 11 eligible studies were selected, including 70 864 patients. The meta‐analysis showed that TDF was superior to ETV with regard to the incidence of HCC, the incidence of death or transplantation, and virologic response. There were no significant differences in terms of biochemical response and loss of seroconversion response among the entire cohort.
Conclusions
The conclusion was that CHB patients treated with TDF had a reduced incidence of HCC compared with patients treated with ETV.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.15036</identifier><identifier>PMID: 32180249</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Chronic hepatitis B ; Clinical trials ; Entecavir ; Hepatitis B ; Hepatocellular carcinoma ; Interferon ; Liver cancer ; Meta-analysis ; Seroconversion ; Systematic review ; Tenofovir ; Transplantation</subject><ispartof>Journal of gastroenterology and hepatology, 2020-09, Vol.35 (9), p.1467-1476</ispartof><rights>2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><rights>2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4196-bc9690cc559bdb08b745f1dcf076df803c366abf13990dc6ce5250775db205683</citedby><cites>FETCH-LOGICAL-c4196-bc9690cc559bdb08b745f1dcf076df803c366abf13990dc6ce5250775db205683</cites><orcidid>0000-0002-1038-0479</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.15036$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.15036$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32180249$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Lihu</creatorcontrib><creatorcontrib>Yao, Qigu</creatorcontrib><creatorcontrib>Shen, Zefeng</creatorcontrib><creatorcontrib>He, Ying</creatorcontrib><creatorcontrib>Ng, Derry Minyao</creatorcontrib><creatorcontrib>Yang, Tong</creatorcontrib><creatorcontrib>Chen, Bangsheng</creatorcontrib><creatorcontrib>Chen, Ping</creatorcontrib><creatorcontrib>Mao, Feiyan</creatorcontrib><creatorcontrib>Yu, Qili</creatorcontrib><title>Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aim
Studies had shown that tenofovir (TDF) and entecavir (ETV) are widely used as the first‐line therapy to inhibit hepatitis B virus replication, which can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it was unclear which nucleos(t)ide analogue was most effective. Therefore, we performed a meta‐analysis and a systematic review to compare the incidence of HCC in CHB patients who are either on TDF or ETV.
Methods
For this study, the following databases were searched for clinical trials published from its inception until November 2019: PubMed, Web of Science, MEDLINE, Embase, and Cochrane Library.
Results
A total of 11 eligible studies were selected, including 70 864 patients. The meta‐analysis showed that TDF was superior to ETV with regard to the incidence of HCC, the incidence of death or transplantation, and virologic response. There were no significant differences in terms of biochemical response and loss of seroconversion response among the entire cohort.
Conclusions
The conclusion was that CHB patients treated with TDF had a reduced incidence of HCC compared with patients treated with ETV.</description><subject>Chronic hepatitis B</subject><subject>Clinical trials</subject><subject>Entecavir</subject><subject>Hepatitis B</subject><subject>Hepatocellular carcinoma</subject><subject>Interferon</subject><subject>Liver cancer</subject><subject>Meta-analysis</subject><subject>Seroconversion</subject><subject>Systematic review</subject><subject>Tenofovir</subject><subject>Transplantation</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp10U1u1DAYBmALUdFpYcEFkCU2dJHWjv9idmVUWqpKbGAdOc6XjkeJPdjJVLPjCNyhN-MkOKSwQMIbW58ev7L1IvSaknOa18X2fnNOBWHyGVpRzklBFZfP0YpUVBSaUX2MTlLaEkI4UeIFOmYlrUjJ9Qo9rsOwM9Gl4HHo8Ag-dGHvIt5DTFPC4EewZh5kEKGdrPP32HnrWvAW5jsb2JkxWOj7qTcRWxOzCYPJCttNDN7ZxbjRJfwBz6ccm97jS5wOaYQhD2wO3zt4wMa3eIDR_Pz-w3jTH5JLL9FRZ_oEr572U_T149WX9U1x9_n60_ryrrCcalk0VktNrBVCN21DqkZx0dHWdkTJtqsIs0xK03SUaU1aKy2IUhClRNuURMiKnaJ3S-4uhm8TpLEeXJr_ZTyEKdUlU0prJUSZ6dt_6DZMMb83K86ZKoWoWFZni7IxpBShq3fRDSYeakrqubk6N1f_bi7bN0-JUzNA-1f-qSqDiwU8uB4O_0-qb69vlshfA-2mYA</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Gu, Lihu</creator><creator>Yao, Qigu</creator><creator>Shen, Zefeng</creator><creator>He, Ying</creator><creator>Ng, Derry Minyao</creator><creator>Yang, Tong</creator><creator>Chen, Bangsheng</creator><creator>Chen, Ping</creator><creator>Mao, Feiyan</creator><creator>Yu, Qili</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1038-0479</orcidid></search><sort><creationdate>202009</creationdate><title>Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis</title><author>Gu, Lihu ; Yao, Qigu ; Shen, Zefeng ; He, Ying ; Ng, Derry Minyao ; Yang, Tong ; Chen, Bangsheng ; Chen, Ping ; Mao, Feiyan ; Yu, Qili</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4196-bc9690cc559bdb08b745f1dcf076df803c366abf13990dc6ce5250775db205683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chronic hepatitis B</topic><topic>Clinical trials</topic><topic>Entecavir</topic><topic>Hepatitis B</topic><topic>Hepatocellular carcinoma</topic><topic>Interferon</topic><topic>Liver cancer</topic><topic>Meta-analysis</topic><topic>Seroconversion</topic><topic>Systematic review</topic><topic>Tenofovir</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Lihu</creatorcontrib><creatorcontrib>Yao, Qigu</creatorcontrib><creatorcontrib>Shen, Zefeng</creatorcontrib><creatorcontrib>He, Ying</creatorcontrib><creatorcontrib>Ng, Derry Minyao</creatorcontrib><creatorcontrib>Yang, Tong</creatorcontrib><creatorcontrib>Chen, Bangsheng</creatorcontrib><creatorcontrib>Chen, Ping</creatorcontrib><creatorcontrib>Mao, Feiyan</creatorcontrib><creatorcontrib>Yu, Qili</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Lihu</au><au>Yao, Qigu</au><au>Shen, Zefeng</au><au>He, Ying</au><au>Ng, Derry Minyao</au><au>Yang, Tong</au><au>Chen, Bangsheng</au><au>Chen, Ping</au><au>Mao, Feiyan</au><au>Yu, Qili</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>35</volume><issue>9</issue><spage>1467</spage><epage>1476</epage><pages>1467-1476</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aim
Studies had shown that tenofovir (TDF) and entecavir (ETV) are widely used as the first‐line therapy to inhibit hepatitis B virus replication, which can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it was unclear which nucleos(t)ide analogue was most effective. Therefore, we performed a meta‐analysis and a systematic review to compare the incidence of HCC in CHB patients who are either on TDF or ETV.
Methods
For this study, the following databases were searched for clinical trials published from its inception until November 2019: PubMed, Web of Science, MEDLINE, Embase, and Cochrane Library.
Results
A total of 11 eligible studies were selected, including 70 864 patients. The meta‐analysis showed that TDF was superior to ETV with regard to the incidence of HCC, the incidence of death or transplantation, and virologic response. There were no significant differences in terms of biochemical response and loss of seroconversion response among the entire cohort.
Conclusions
The conclusion was that CHB patients treated with TDF had a reduced incidence of HCC compared with patients treated with ETV.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32180249</pmid><doi>10.1111/jgh.15036</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1038-0479</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2020-09, Vol.35 (9), p.1467-1476 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2377997552 |
| source | Access via Wiley Online Library |
| subjects | Chronic hepatitis B Clinical trials Entecavir Hepatitis B Hepatocellular carcinoma Interferon Liver cancer Meta-analysis Seroconversion Systematic review Tenofovir Transplantation |
| title | Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A59%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20tenofovir%20versus%20entecavir%20on%20reducing%20incidence%20of%20hepatocellular%20carcinoma%20in%20chronic%20hepatitis%20B%20patients:%20A%20systematic%20review%20and%20meta%E2%80%90analysis&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Gu,%20Lihu&rft.date=2020-09&rft.volume=35&rft.issue=9&rft.spage=1467&rft.epage=1476&rft.pages=1467-1476&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.15036&rft_dat=%3Cproquest_cross%3E2443725583%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2443725583&rft_id=info:pmid/32180249&rfr_iscdi=true |